Clinical Trials Sponsored by Henlix, Inc

Total 35812 results

Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Henlix, Inc

Unknown

Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status

Solid Tumor, Adult

Taiwan
Henlix, Inc

Completed

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Solid Tumour

Taiwan, United States
Henlix, Inc

Unknown

Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients

Hepatitis B, Chronic

Taiwan
Illumina, Inc.
Helix OpCo, LLC

Completed

Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population

SARS-CoV-2

United States
Illumina, Inc.
Helix OpCo, LLC

Completed

Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel

SARS-CoV-2

United States
Helio Genomics
Helio Health Inc., Irvine, CA

Enrolling by invitation

HELIO Liver Test Performance Study in China (HEPATIC) (HEPATIC)

Hepatocellular Carcinoma and Liver Disease

China
Helix Medical Systems

Terminated

Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis

Breast Cancer

Israel
Helix BioPharma Corporation
Theradex

Completed

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Non-Small Cell Lung Cancer

United States
Helix BioPharma Corporation
Theradex

Recruiting

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

Pancreas Cancer

United States
Helio Genomics
Helio Health Inc., Irvine, CA; Laboratory for Advanced Medicine, Guangzhou

Completed

Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCC (ENCORE)

Hepatocellular Carcinoma by AJCC Stage

China
Shanghai Henlius Biotech

Recruiting

A Study of HLX42 in Advanced/Metastatic Solid Tumors

Solid Tumor

China
Shanghai Henlius Biotech

Recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Healthy Male Volunteers

China
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Shanghai Henlius Biotech

Not yet recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

Solid Tumor, Adult Lymphoma
Shanghai Henlius Biotech

Not yet recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Solid Tumor
Shanghai Henlius Biotech

Not yet recruiting

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor, Adult
Shanghai Henlius Biotech

Recruiting

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma (HLX301)

Lymphoma | Advanced Tumors | Metastatic Tumors

China
Shanghai Henlius Biotech

Not yet recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Small-cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer

United States, China, Greece, Spain, Austria, Czechia, Germany, Hungary, Latvia, Netherlands, Poland
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Advanced Melanoma

China
Shanghai Henlius Biotech

Recruiting

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

Solid Tumor and Lymphoma

China
Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China
Shanghai Henlius Biotech

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Postmenopausal

China
Shanghai Henlius Biotech

Active, not recruiting

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Squamous-cell Non-small Cell Lung Cancer

China
Shanghai Henlius Biotech

Completed

The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (HLX07Ib/II)

Advanced Solid Tumors

China
Shanghai Henlius Biotech

Withdrawn

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Advanced Solid Tumor

United States
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Extensive Stage Small Cell Lung Cancer

China, Georgia, Poland, Russian Federation, Turkey, Ukraine
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects

Healthy

China
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Shanghai Henlius Biotech

Completed

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

Healthy Male Subjects

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

Cervical Cancer

China
Shanghai Henlius Biotech

Completed

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
Helix BioPharma Corporation
KCR S.A.

Terminated

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Lung Adenocarcinoma

Poland, Ukraine
Helio Genomics

Recruiting

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer (ELITE)

Liver Cirrhosis | Diabetes | Cancer | Hepatitis B | Hepatitis C | COPD | Chronic Hepatitis

United States
Healx Limited

Withdrawn

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 (IMPACT-FXS)

Fragile X Syndrome

United States, Australia
Aelix Therapeutics

Completed

Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)

HIV

Spain
Shanghai Henlius Biotech

Not yet recruiting

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
Shanghai Henlius Biotech

Not yet recruiting

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects

IPF
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
Shanghai Henlius Biotech

Recruiting

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Extensive Stage Small Cell Lung Cancer

United States
Shanghai Henlius Biotech

Not yet recruiting

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor

China
Shanghai Henlius Biotech

Not yet recruiting

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Shanghai Henlius Biotech

Recruiting

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Shanghai Henlius Biotech

Recruiting

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Non-small Cell Lung Cancer | Locally Advanced or Metastatic Solid Tumors

Australia

3

Subscribe